MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary


Drug Safety Update

 December 2014: Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive.

 December 2014: High-dose cyproterone acetate: potential risk of (multiple) meningiomas.

April 2020: Restrictions in use of cyproterone acetate due to risk of meningioma

June 2020: Cyproterone acetate: new advice to minimise risk of meningioma

Increased risk of venous thromboembolism

Pack Price
63 tablet (3 x 21 tablets) £10.76